索拉非尼
二甲双胍
下调和上调
肝细胞癌
癌症研究
转移
体内
医学
内科学
癌症
化学
生物
生物化学
基因
生物技术
胰岛素
作者
Zongyou Guo,Manqing Cao,A-Bin You,Junrong Gao,Hongyuan Zhou,Huikai Li,Yunlong Cui,Fang Fěng,Wei Zhang,Tianqiang Song,Qiang Li,Xiaolin Zhu,Hui–Chuan Sun,Ti Zhang
出处
期刊:Cancer Science
[Wiley]
日期:2016-02-23
卷期号:107 (4): 507-513
被引量:32
摘要
We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression. More recently, metformin has been shown to have potential as a preventive and therapeutic agent for different cancers, including HCC. This study evaluated whether the combination of sorafenib and metformin is sufficient to revert the expression of TIP30, thereby simultaneously reducing lung metastasis and improving survival. Our data show that the combination of sorafenib and metformin inhibits proliferation and invasion in vitro , prolongs median survival, and reduces lung metastasis of HCC in vivo . This effect is closely associated with the upregulation of TIP30, partly through activating AMP‐activated protein kinase. Thioredoxin, a prometastasis factor, is negatively regulated by TIP30 and plays an essential role during the process of HCC metastasis. Overall, our results suggest that metformin might be a potent enhancer for the treatment of HCC by using sorafenib.
科研通智能强力驱动
Strongly Powered by AbleSci AI